Education
About Us
Working with TipRanks
Follow Us
Corbion NV (NL:CRBN)
:CRBN
Top Page
Corbion NV
(LSE:CRBN)
Rating:68Neutral
Price Target:
€20.50
▲(8.75%Upside)
Corbion NV (CRBN) vs. iShares MSCI Netherlands ETF (EWN)
Market Cap
€1.09B
Dividend Yield3.21%
Average Volume (3M)129.91K
Price to Earnings (P/E)20.3
Beta (1Y)1.16
Revenue Growth-10.78%
EPS Growth-24.58%
CountryNL
Employees2,383
SectorBasic Materials
Sector Strength65
IndustryChemicals - Specialty
Share Statistics
EPS (TTM)0.93
Shares Outstanding58,250,310
10 Day Avg. Volume109,357
30 Day Avg. Volume129,911
Financial Highlights & Ratios
PEG Ratio19.93
Price to Book (P/B)1.55
Price to Sales (P/S)0.00
P/FCF Ratio16.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€24.50Price Target Upside29.97% Upside
Rating ConsensusHold
Number of Analyst Covering2
Corbion NV Business Overview & Revenue Model
Company DescriptionCorbion N.V. provides lactic acid and lactic acid derivatives, emulsifiers, functional enzyme blends, minerals, vitamins, and algae ingredients worldwide. The company offers ingredient solutions made from renewable resources for the food, home and personal care, pharmaceutical, animal nutrition, medical device, and bioplastics markets. It markets its products through a network of sales offices and distributors. The company was formerly known as CSM N.V. and changed its name to Corbion N.V. in October 2013. Corbion N.V. was founded in 1919 and is headquartered in Amsterdam, the Netherlands.
How the Company Makes MoneyCorbion NV generates revenue through the production and sale of bio-based ingredients. Its primary revenue streams are derived from its two main business segments: Food Ingredients and Biochemicals. In the Food Ingredients segment, Corbion supplies preservatives, emulsifiers, and other functional ingredients to food manufacturers, focusing on improving food safety, shelf life, and nutritional content. The Biochemicals segment provides sustainable solutions for a wide range of industries, including bioplastics, pharmaceuticals, and agriculture, through the supply of lactic acid and derivatives. Corbion's strategic partnerships and collaborations, particularly in the bioplastics sector, enhance its market penetration and innovation capabilities, contributing to its earnings. The company's focus on sustainability and innovation in product development further strengthens its market position and revenue potential.
Corbion NV Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 1.24B | 1.44B | 1.46B | 1.07B | 986.50M | 976.40M | Gross Profit |
| 282.10M | 352.70M | 324.30M | 265.80M | 269.80M | 198.70M | EBIT |
| 56.80M | 117.20M | 103.60M | 72.30M | 98.00M | -2.80M | EBITDA |
| 133.10M | 198.00M | 194.00M | 133.10M | 154.90M | 118.30M | Net Income Common Stockholders |
| 62.60M | 72.90M | 90.00M | 78.30M | 73.10M | 25.80M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 45.70M | 70.20M | 58.20M | 42.20M | 51.60M | 45.70M | Total Assets |
| 1.12B | 1.70B | 1.72B | 1.36B | 1.09B | 1.12B | Total Debt |
| 349.00M | 785.50M | 759.20M | 503.20M | 335.80M | 349.00M | Net Debt |
| 303.30M | 715.30M | 701.00M | 461.00M | 284.20M | 303.30M | Total Liabilities |
| 586.20M | 1.06B | 1.10B | 806.50M | 578.20M | 586.20M | Stockholders Equity |
| 529.10M | 636.20M | 625.70M | 554.10M | 516.00M | 529.10M |
| Cash Flow | Free Cash Flow | ||||
| -176.70M | 16.10M | -182.60M | -122.00M | 24.50M | 39.50M | Operating Cash Flow |
| 31.90M | 165.40M | 53.20M | 26.70M | 113.40M | 115.70M | Investing Cash Flow |
| -183.90M | -146.80M | -213.30M | -123.70M | -81.30M | -106.10M | Financing Cash Flow |
| 183.60M | -5.30M | 173.90M | 85.90M | -23.90M | -12.00M |
Corbion NV Technical Analysis
Positive
18.85
Price Trends
18.51
Positive
19.91
Negative
21.09
Negative
Market Momentum
0.11
Negative
55.38
Neutral
41.87
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NL:CRBN, the sentiment is Positive. The current price of 18.85 is above the 20-day moving average (MA) of 18.69, above the 50-day MA of 18.51, and below the 200-day MA of 21.09, indicating a neutral trend. The MACD of 0.11 indicates Negative momentum. The RSI at 55.38 is Neutral, neither overbought nor oversold. The STOCH value of 41.87 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NL:CRBN.
Corbion NV Peers Comparison
Overall Rating
UnderperformOutperform
Sector (50)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | €7.21B | 25.12 | 14.13% | 1.77% | 6.41% | -5.29% | |
71 Outperform | €10.15B | 21.69 | 10.15% | 3.34% | 0.31% | -11.62% | |
70 Outperform | €1.93B | 8.43 | 6.92% | 6.29% | -1.84% | 345.98% | |
68 Neutral | €1.09B | 20.30 | 6.52% | 3.21% | -10.78% | -24.58% | |
50 Neutral | $2.00B | -1.14 | -21.15% | 3.68% | 2.17% | -31.00% | |
48 Neutral | €1.63B | 58.27 | 41.95% | -66.11% | -202.16% |
* Basic Materials Sector Average
Performance Comparison
NL:CRBN
Corbion NV
18.85
-1.56
-7.65%
NL:IMCD
IMCD N.V.
121.25
-17.45
-12.58%
NL:APAM
Aperam S.A.
27.08
2.20
8.83%
NL:OCI
OCI N.V.
7.85
1.30
19.76%
NL:AKZA
Akzo Nobel NV
59.28
-2.50
-4.05%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.